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166Decompensated Heart Failure) trial highlight the high post-
discharge morbidity and mortality (w50% to 60% at 60 days) in
patients with cardiorenal syndrome who have undergone aggressive
volume removal by either diuretics or ultraﬁltration (9). We propose
that rather than targeting volume removal to treat HHF, a more
rational approachwould be to assess the relative degrees of excess total
body salt and water versus redistribution of existing volume, and to
direct therapy towards the underlying cause of the congestion.*Mark E. Dunlap, MD
Paul A. Sobotka, MD
*MetroHealth Campus of Case Western Reserve University
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Congestion, caused by elevated ventricular ﬁlling pressures, is
the primary cause of most admissions and re-admissions for heart
failure (HF). Congestion can develop rapidly with minimal warning
signs or preceding weight gain, perhaps due to a mismatch between
acute changes in afterload and/or ventricular compliance. More
commonly, congestion occurs as a gradual, insidious process as
a result of a number of cardiac and noncardiac processes, including
progression of HF (2).Dunlap and Sobotka highlight the subset of patients who may
not experience signiﬁcant weight gain before admission. Even
subtle changes in weight post-discharge are strong predictors of
re-hospitalization, with a speciﬁcity approaching 90% (3). Thus,
large perturbations in body weight over a matter of days are strongly
indicative of impending necessity for HF hospitalization. Weight
gain may not precede all admissions (poor sensitivity), but alter-
native mechanisms of congestion are difﬁcult to measure based on
available modalities and may not relate to clinical outcomes. In
2013, measurement of daily weights, albeit crude, remains one of
the most feasible approaches to outpatient monitoring of conges-
tion in terms of costs, patient accessibility, and portability of
information. Emerging technologies may help boost our ability to
detect congestion at an early pre-admission stage.
Aggressive decongestion, via primarily diuresis, remains a major
treatment modality in patients hospitalized for HF. The majority of
patients experience early dyspnea relief with the use of standard
diuretic regimens, suggesting that volume overload underlies their
symptomatic presentation (4). Hemoconcentration, even in the face
of inpatient worsening renal function, has been associated with
improved mortality (5). Inpatient weight loss and net ﬂuid loss
are associated with improved clinical outcomes at 60 days post-
discharge (6). Despite the focus on aggressive decongestion, 40%
to 50% of patients do not experience signiﬁcant weight loss during
hospitalization. This may reﬂect inadequate decongestion. Optimal
ﬂuid removal strategies and duration of and intensity of inpatient
therapy are topics that require further investigation. Although
volume re-distribution over a short period of time may result in
congestion, gradual ﬂuid overload appears to be the major driver of
subsequent events. As such, monitoring and therapeutic interven-
tions targeting ﬂuid overload may be necessary to reduce hospi-
talizations and re-hospitalizations.Muthiah Vaduganathan, MD, MPH
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*Mihai Gheorghiade, MD
*Center for Cardiovascular Innovation
Feinberg School of Medicine
Northwestern University




Please note: Dr. Fonarow has received research support from the Agency for Healthcare
Research and Quality (signiﬁcant) and is a consultant for Medtronic (modest) and
Novartis (signiﬁcant). Dr. Gheorghiade is a consultant for Abbott Laboratories
(modest), Astellas (modest), AstraZeneca (modest), Bayer Schering Pharma AG
(signiﬁcant), CorThera, Inc. (modest), Cytokinetics, Inc. (modest), DebioPharm SA
(signiﬁcant), Errekappa Terapeutici (Milan, Italy) (modest), GlaxoSmithKline
(modest), Johnson & Johnson (modest), Medtronic (signiﬁcant), Merck (modest),
Novartis Pharma AG (signiﬁcant), Otsuka Pharmaceuticals (signiﬁcant), Pericor
Therapeutics (signiﬁcant), Protein Design Laboratories (modest), Sanoﬁ-Aventis
(modest), Sigma Tau (signiﬁcant), and Solvay Pharmaceuticals (signiﬁcant).
Drs. Vaduganathan and Bonow have reported that they have no relationships relevant to
the contents of this paper to disclose.REFERENCES
1. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Reho-
spitalization for heart failure: problems and perspectives. J Am Coll
Cardiol 2013;61:391–403.
JACC Vol. 62, No. 2, 2013 Correspondence
July 9, 2013:162–8
1672. Gheorghiade M, Filippatos G, De Luca L, et al. Congestion in acute
heart failure syndromes: an essential target of evaluation and treatment.
Am J Med 2006;119 2 Suppl 1:S3–10.
3. Blair JE, Khan S, Konstam MA, et al. Weight changes after hospitali-
zation for worsening heart failure and subsequent re-hospitalization
and mortality in the EVEREST trial. Eur Heart J 2009;30:1666–73.
4. Ambrosy AP, Pang PS, Khan S, et al. Clinical course and predictive value
of congestion during hospitalization in patients admitted for worsening
signs and symptoms of heart failure with reduced ejection fraction:
ﬁndings from the EVEREST trial. Eur Heart J 2013;34:835–43.
5. Testani JM, Chen J, McCauley BD, et al. Potential effects of
aggressive decongestion during the treatment of decompensated heart
failure on renal function and survival. Circulation 2010;122:265–72.
6. Kociol RD, McNulty SE, Hernandez AF, et al. Markers of deconges-
tion, dyspnea relief and clinical outcomes among patients hospitalized
with acute heart failure. Circ Heart Fail 2013;6:240–5.Impact of Rate and Rhythm
on Atrial Thrombogenesis in
Atrial Fibrillation
Which Takes Priority?We read with interest the clinical study by Lim et al. (1) in which
rapid atrial rate and atrial ﬁbrillation (AF) both resulted in
increased platelet activation and thrombin generation in humans,
but AF additionally induced endothelial dysfunction and inﬂam-
mation. They concluded that although the rapid atrial rate
increased the thrombogenic risk, AF might further potentiate this
risk. Nevertheless, we consider that there are several controversial
aspects that could reduce the value of this conclusion.
In their study, they enrolled both paroxysmal and persistent AF
patients. In fact, the extent and the source of inﬂammation might
be different across all types of AF. Kamath et al. (2) found that
abnormal platelet activation in patients with permanent AF was not
consistently observed in those with paroxysmal and persistent AF.
Also, a recent study by Scridon et al. (3) found higher left atrial
vascular endothelial growth factor levels in paroxysmal AF, but not
in persistent AF. Furthermore, we wonder how long have these
patients with persistent AF been in sinus rhythm following car-
dioversion? The inﬂammatory status in persistent AF following
cardioversion has not been clearly established. Electrical car-
dioversion of the patients with persistent AF did not signiﬁcantly
alter levels of von Willebrand factor, soluble P-selectin, or ﬁbrin-
ogen, despite maintenance of sinus rhythm at 3 months (4).
Contrary to these results, Kamath et al. (2) demonstrated a signif-
icant decrease in plasma soluble P-selectin levels in patients with
persistent AF who remained in sinus rhythm at 2 weeks and
2 months following successful cardioversion. This inconsistency
merits further investigation. Therefore, a limited number of
patients combined with variable types of AF made the evaluation of
inﬂammatory status in the present study less accurate.
A rapid atrial rate and rhythm disturbances are 2 characteristics
of AF. The main ﬁnding in the present study that AF additionally
induced endothelial dysfunction and inﬂammation is another
controversy. In fact, the impact of rhythm on thrombogenesis in
AF is still controversial. The increased asymmetric dimethylargi-
nine (ADMA) levels and reduced mRNA expression of ventricularand aortic endothelial nitric oxide synthase (eNOS) by rapid atrial
pacing in the study by Goette et al. (5) were mainly due to the rapid
atrial rate. Although there was no difference in ventricular rate
between the AF and atrial pacing groups, it should be noted that
the atrial rate was statistically much higher in the AF group than
the atrial pacing group (293.1  58.0 vs. 150.0  0 beats/min,
p < 0.01). Therefore, it was much more possible that the higher
atrial rate in the AF group caused additional induced ADMA and
platelet-derived inﬂammation (sCD40L). At least until now, we
could not perceive of any convincing evidence that the abnormal
rhythm dominated atrial thrombogenesis in AF. The conclusion
that AF additionally induced endothelial dysfunction and inﬂam-
mation in the present study seems misleading to some extent.
Although the mechanisms of atrial thrombogenesis in AF have
been well documented (6,7), the individual impact of rate and
rhythm is still inconclusive. Nevertheless, Lim et al. (1) enlightened
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interest in our work (1). Previous studies on prothrombotic markers
such as platelet activation in atrial ﬁbrillation (AF) patients have
yielded conﬂicting results. This could be due to several factors.
First, different sampling sitesdwe have found from previous
studies and this study that atrial sampling yielded abnormal platelet
activation and increased thrombogenesis that was not reﬂected in
